{"id":763,"date":"2026-02-11T14:55:17","date_gmt":"2026-02-11T14:55:17","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/763\/"},"modified":"2026-02-11T14:55:17","modified_gmt":"2026-02-11T14:55:17","slug":"roche-sees-steady-2026-growth-as-key-drugs-post-double-digit-gains-roche-holding-otcrhhby","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/763\/","title":{"rendered":"Roche Sees Steady 2026 Growth As Key Drugs Post Double-Digit Gains – Roche Holding (OTC:RHHBY)"},"content":{"rendered":"

Roche Holdings AG (OTC:<\/a>RHHBY<\/a>) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7% (+2% in CHF) due to strong demand for pharmaceutical products and diagnostic solutions.<\/p>\n

Core operating profit increased<\/a> by 13% (5% in CHF) to CHF 21.8 billion, driven by higher sales and efficiency gains.<\/p>\n

Core EPS increased 11% (+4% in CHF) to CHF 19.46 ($24.35).<\/p>\n

Segment Performance<\/p>\n

Sales in the Pharmaceuticals Division increased by 9% (3% in CHF) to CHF 47.7 billion, with medicines for severe diseases<\/a> continuing their strong growth.<\/p>\n

The top five growth drivers \u2013 Phesgo, Xolair, Ocrevus, Hemlibra, and Vabysmo \u2013 achieved total sales of CHF 21.4 billion, an increase of CHF 3.2 billion (CER) compared to 2024.<\/p>\n

Ocrevus sales were up 9% to CHF 7.01 billion, Hemlibra sales jumped 11% to CHF 4.75 billion, Vabysmo sales increased 12% to CHF 4.10 billion, Xolair sales were up 32% to CHF 3.07 billion, and<\/p>\n

Phesgo revenues rose 48% to CHF 2.44 billion.<\/p>\n

Sales of products with expired patents \u2013 Avastin (various types of cancer drug), Herceptin (breast and gastric cancer), MabThera\/Rituxan (blood cancer, rheumatoid arthritis), Esbriet (lung disease), Lucentis (severe eye diseases), and Actemra\/RoActemra (rheumatoid arthritis) \u2013 decreased by a combined CHF 0.7 billion (CER).<\/p>\n

The Diagnostics Division’s sales increased by 2% (-3% in CHF) to CHF 13.8 billion as growth in demand for pathology and molecular solutions more than offset the impact of healthcare pricing reforms in China.<\/p>\n

Roche CEO Thomas Schinecker on Thursday commented, “2025 was a strong year for Roche, reflecting our continued focus on operational and R&D excellence.\u201d<\/p>\n

\u201cWe are also setting new standards in diagnostics: our next-generation sequencing technology, which will be launched this year, decoded an entire human genome in less than four hours,\u201d Schinecker added.<\/p>\n

Outlook for 2026<\/p>\n

Roche expects an increase in sales in the mid single-digit range (CER). Core earnings per share are targeted to develop in the high single-digit range (CER).<\/p>\n

Dividend Increase<\/p>\n

Roche expects to increase its dividend in Swiss francs. The board proposed a dividend increase to CHF 9.80 per share and a non-voting equity security. If approved by shareholders, this would be the 39th consecutive dividend increase.<\/p>\n

RHHBY Price Action: Roche Holding shares were up 2.79% at $55.91 at the time of publication on Thursday. The stock is approaching its 52-week high of $57.29, according to Benzinga Pro data<\/a>.<\/p>\n

Photo by OleksSH via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holdings AG (OTC:RHHBY) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7%…\n","protected":false},"author":2,"featured_media":310,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,1014,1016,1015,344,914,346,343,345,341,340,134,347],"class_list":{"0":"post-763","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-earnings","10":"tag-category-general","11":"tag-category-guidance","12":"tag-category-health-care","13":"tag-category-large-cap","14":"tag-category-movers","15":"tag-category-news","16":"tag-category-top-stories","17":"tag-cms-wordpress","18":"tag-pageisbzpro-bz","19":"tag-roche","20":"tag-symbol-rhhby"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=763"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/763\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/310"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}